VRX – Valeant Pharmaceuticals International, Inc – develops, manufactures and sells pharmaceuticals, OTC products and medical devices. Previously this week, $VRX prices had slumped due to bankruptcy scare. Chances are, it may plunge further, despite a 5% rise pre-market.
VRX- Valeant Pharmaceuticals International, Inc.
|Fundamentals||Previously closed at||26.69|
|Analysts opinion||With the news VRX postponing its annual report filing with SEC due to an ongoing investigation of its finances, and weak forecasts for 2016, the stocks plummeted to new lows in 5 years. The stock has lost atleast 85% of its value since its 1 year high. Today, the CEO, Mike Pearson sent out a memo, assuring the employees, that VRX will not be filing for bankruptcy. It also stated that, it would miss a deadline to file its annual report, which would risk Valeant pharma to fall into defaulting some of its debt unless the annual report was filed within the 60-day cure.|
|Sentiments||The stock rose 5% pre-market, but has mixed sentiments from investors. While some investors are bullish due to CEO’s memo, many are bearish due to the associated risks.|
|Social Pulse||The stock has 100% higher social chatter than usual.|